Remote ischemic preconditioning (RIPC) has been described as a potential means of reducing ischemia-reperfusion injury (IRI) in various tissues. This mechanism has been proven mainly in animal models, but with increasing frequency, clinical studies are proposing possible analogous benefits in patients. However, questions arise with regard to the real therapeutic magnitude: is RIPC really such a useful weapon against occasionally lethal IRI?
展开▼
